MSD’s ADC gains OS win but PFS miss in Phase III stomach cancer trial
MSD’s TROP2-targeting antibody-drug conjugate (ADC), sacituzumab tirumotecan (sac-TMT), has offered a significant overall survival (OS) benefit in another Phase III …
MSD’s TROP2-targeting antibody-drug conjugate (ADC), sacituzumab tirumotecan (sac-TMT), has offered a significant overall survival (OS) benefit in another Phase III …
Throughout the years, Europe has been a cornerstone of the global clinical trials landscape, supported by established academic institutions and …
A Phase II trial of an umbilical cord stem cell-based therapy as a treatment for adults with active systemic lupus …
Swiss biopharmaceutical company BioVersys’ antibiotic combination, AlpE, has offered bacteria-killing benefits in a mid-stage tuberculosis (TB) study – a development …
At a time when innovative medicines with new mechanisms of action (MOA) are growing at pace thanks to artificial intelligence …
Emmecell has dosed the first patient in its Phase II EMERALD trial of EO2002, an investigational cell therapy for adults …
Artificial intelligence (AI) is being used in all areas of clinical trials, from patient recruitment to data analysis, including protocol …
Bristol Myers Squibb’s (BMS) next-generation antipsychotic therapy, Cobenfy (xanomeline and trospium chloride), has been shown to trigger improvements in hallucinations …
Biogen has reported two-year data from its Phase II CELIA trial showing that diranersen (BIIB080) slowed clinical decline in early …
Multimorbidity prevalence, defined as the co-occurrence of two or more co-existing chronic conditions within an individual, has been steadily rising …
While Priavoid’s oral Alzheimer’s disease drug has been shown to be safe and tolerable, it failed to have a significant …
ONL Therapeutics has concluded patient enrolment in its global Phase II GALAXY clinical trial assessing xelafaslatide for geographic atrophy (GA) …
Sellas Life Sciences’ stock value has soared nearly 150% after its off-the-shelf cancer vaccine, galinpepimut-S (GPS), improved survival outcomes in …
This year marks two decades since the first biosimilar was approved in Europe in 2006. Since then, approximately 165 European …
MSD has discontinued its Phase III BELLWAVE-011 trial assessing nemtabrutinib (MK-1026) for leukaemia and other haematologic malignancies after an external …